Objective: This study is to evaluate the efficacy, tolerability and adverse effects of a triple second line therapy including of Rabeprazole, Amoxicilin và Levofloxacin in patients who have failed first-line Helicobacter pylory (H.Pylori) therapy. Methods: By descriptive cross-sectional study, the authors have examined 101 gastro-duodenitis patients, who had failed first treatment with standard triple therapy, received 10-days therapy including Rabeprazole (20mg b.d), Levofloxacin (500mg b.d) and Amoxycillin (1g b.d). Eradication is confirmed with by the C13-urea breat h test after 4 weeks from completing of treatment. Results: 100% of patients are initially included and noboby is lost for follow-up. Mean age was 44 yr, 38% were male, 68,3% had duodenitis, 20,7% gastritis, 11% gastro-duodenitis. All patients took medications correctly. Per-protocol and intention to treat eradication rates were both 83,3% (95% CI=75,4-91,3). Mild adverse effects were reported overall in 8% of the patients, mainly including rash 2%, myalgias 2% and diarrhea 5%, none of them were severe. Conclusion: This ten-days levofloxacin-base therapy represents an alternative to standard quadruple therapy in patents with previous PPI-Clarithromycin-Amoxicillin failure, being effective, safe and simple.